EPCAM and neoplasm: In patients undergoing LT, LR, transarterial chemoembolization (TACE), or radiotherapy for HCC, EpCAM+ CTC count at baseline has been associated with increased tumor recurrence, shorter overall survival, and shorter progression-free survival [26,54,55,60].